Shivalik Rasayan has successfully filed a Drug Master File with the USFDA for its Avapritinib API, used to treat gastrointestinal tumors. With the assessment phase complete, the company is now positioned to supply this ingredient to manufacturers targeting the US market, potentially tapping into the high-demand segment currently dominated by the branded Ayvakit.
Shivalik Rasayan Advances USFDA Pipeline with Avapritinib DMF
Key Filing: Successfully filed Drug Master File (DMF) for Avapritinib API with USFDA.
Regulatory Milestone: Complete Assessment (CA) has been finalized for the API filing.
Reader Takeaway: Regulatory progress into the US oncology market; commercial supply contracts are the next key milestone for growth.
What just happened
Shivalik Rasayan Limited has officially confirmed the filing of a Drug Master File (DMF) for Avapritinib, an Active Pharmaceutical Ingredient (API) used in the treatment of Gastrointestinal Stromal Tumors (GIST). The company reached a significant regulatory milestone by completing the 'Complete Assessment' (CA) phase with the US Food and Drug Administration (USFDA). This move signifies that Shivalik Rasayan's API meets the necessary regulatory standards required for potential integration into finished dosage forms for the US pharmaceutical market.
Why this matters
DMF filings are essential for any API manufacturer aiming to supply ingredients to companies producing finished drugs for the regulated US market. By finalizing the assessment, Shivalik Rasayan effectively removes a major regulatory hurdle. The product targets the market space occupied by Sanofi’s branded drug, Ayvakit, which reported revenues of 700 million USD in 2025. This creates a potential path for Shivalik Rasayan to participate in the supply chain for this oncology treatment as generic or alternative manufacturers look for reliable API sources.
What to track next
The immediate focus for investors should be on the company's ability to convert this regulatory milestone into concrete commercial outcomes. Key areas to monitor include:
- Announcement of supply agreements with US-based or international pharmaceutical companies.
- Updates on capacity utilization for the Avapritinib API line.
- Any further regulatory certifications required for full-scale commercial manufacturing and export.